R&D Cuts Curb Brain-Drug Pipeline

This article predicts that neuroscience research faces funding cuts as major biotechnology and pharmaceutical companies look to maintain profits by lowering research and development costs. In contrast, the article claims that heart disease, cancer, diabetes, and autoimmune and infectious diseases will remain priorities for drug development.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail